ATE472538T1 - 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden - Google Patents

8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden

Info

Publication number
ATE472538T1
ATE472538T1 AT06777337T AT06777337T ATE472538T1 AT E472538 T1 ATE472538 T1 AT E472538T1 AT 06777337 T AT06777337 T AT 06777337T AT 06777337 T AT06777337 T AT 06777337T AT E472538 T1 ATE472538 T1 AT E472538T1
Authority
AT
Austria
Prior art keywords
disorders
parkinson
disease
compounds
formula
Prior art date
Application number
AT06777337T
Other languages
English (en)
Inventor
Alexander Alanine
Luca Claudio Gobbi
Sabine Kolczewski
Thomas Luebbers
Jens-Uwe Peters
Lucinda Steward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE472538T1 publication Critical patent/ATE472538T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06777337T 2005-06-27 2006-06-16 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden ATE472538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105699 2005-06-27
PCT/EP2006/063269 WO2007000393A1 (en) 2005-06-27 2006-06-16 8-alk0xy-4-methyl-3 , 4-dihydr0-quinaz0lin-2-yl amines and their use as 5-ht5a receptor ligands

Publications (1)

Publication Number Publication Date
ATE472538T1 true ATE472538T1 (de) 2010-07-15

Family

ID=37149153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777337T ATE472538T1 (de) 2005-06-27 2006-06-16 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden

Country Status (14)

Country Link
US (1) US7790733B2 (de)
EP (1) EP1899307B1 (de)
JP (1) JP4769867B2 (de)
KR (1) KR100950629B1 (de)
CN (1) CN101208308B (de)
AT (1) ATE472538T1 (de)
AU (1) AU2006263925A1 (de)
BR (1) BRPI0613693A2 (de)
CA (1) CA2612478A1 (de)
DE (1) DE602006015193D1 (de)
ES (1) ES2345724T3 (de)
IL (1) IL188115A (de)
MX (1) MX2007015777A (de)
WO (1) WO2007000393A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009484A (es) * 2007-03-05 2010-06-01 Benz Res & Dev Corp Filtros de luz que comprenden un cromoforo que se presenta en la naturaleza y derivados de los mismos.
CA2699697A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
FR2930891B1 (fr) * 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005035A1 (en) * 1991-09-06 1993-03-18 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
JP2007510642A (ja) 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬

Also Published As

Publication number Publication date
WO2007000393A1 (en) 2007-01-04
ES2345724T3 (es) 2010-09-30
MX2007015777A (es) 2008-02-22
BRPI0613693A2 (pt) 2011-01-25
IL188115A (en) 2011-09-27
EP1899307B1 (de) 2010-06-30
EP1899307A1 (de) 2008-03-19
CN101208308B (zh) 2010-12-08
KR20080014082A (ko) 2008-02-13
US7790733B2 (en) 2010-09-07
KR100950629B1 (ko) 2010-04-01
AU2006263925A1 (en) 2007-01-04
CN101208308A (zh) 2008-06-25
JP2008546823A (ja) 2008-12-25
DE602006015193D1 (de) 2010-08-12
US20060293350A1 (en) 2006-12-28
JP4769867B2 (ja) 2011-09-07
IL188115A0 (en) 2008-03-20
CA2612478A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
MX2009005509A (es) 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
ATE454380T1 (de) Organische verbindungen zur behandlung entzündlicher oder allergischer leiden
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
WO2005090296A3 (en) N-substituted benzene sulfonamides
MX2010009403A (es) Derivados de 2-aminoquinolina.
ATE466858T1 (de) 3-arylisoxazol-4-carbonylbenzofuranderivative
IL188115A0 (en) 8-alkoxy-4-methyl-3,4-dihdro-quinazolin-2-
WO2010026110A3 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
MX2010009820A (es) 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.
MX2010008239A (es) 2-aminoquinolinas.
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
ATE523199T1 (de) Pyridazinverbindungen und verfahren
JP2006519251A5 (de)
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
ATE461190T1 (de) Substituierte pyradinon-derivate als alpha2- adrenorezeptor-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899307

Country of ref document: EP